Company Encyclopedia
View More
name
Bioceres Crop Solutions
BIOX.US
Bioceres Crop Solutions Corp., together with its subsidiaries, develops and commercializes crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier and higher yielding crops. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits.
158.94 B
BIOX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Fertilizers and Agricultural ChemicalsIndustry
Industry Ranking13/14
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-19.85%E
    • Profit Margin-17.72%D
    • Gross Margin45.56%B
  • Growth ScoreE
    • Revenue YoY-27.90%E
    • Net Profit YoY-2356.74%E
    • Total Assets YoY-11.17%E
    • Net Assets YoY-16.67%E
  • Cash ScoreE
    • Cash Flow Margin-564.36%E
    • OCF YoY-27.90%E
  • Operating ScoreC
    • Turnover0.41C
  • Debt ScoreD
    • Gearing Ratio60.77%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Bioceres Crop Solutions (BIOX) Receives a Hold from Canaccord Genuity

    Canaccord Genuity's Austin Moeller maintains a Hold rating on Bioceres Crop Solutions with a $2.25 price target. Moeller, a 4-star analyst, has a 7.9% average return and a 41.15% success rate. The consensus rating for Bioceres is Hold, with an average price target of $11.08.

    Tip Ranks·
    US
    BIOX
    -0.63%
    Tip Ranks·
    US
    BIOX
    -0.63%

    Bioceres Crop Solutions Reports Q1 2026 Earnings

    Bioceres Crop Solutions reported Q1 2026 earnings with $77.5 million in revenue, a 17% decline from last year due to strategic shifts. Despite this, gross profit rose to $36.2 million with a 47% margin. Operating profit increased to $7.1 million, but net loss widened to $7.5 million due to higher costs. Adjusted EBITDA grew 61% to $13.6 million. The company aims to enhance revenue quality and financial flexibility for long-term resilience.

    Tip Ranks·
    US
    BIOX
    -0.63%
    Tip Ranks·
    US
    BIOX
    -0.63%

    Bioceres Crop Solutions (NASDAQ:BIOX) Posts Earnings Results, Misses Expectations By $0.08 EPS

    Bioceres Crop Solutions (NASDAQ:BIOX) reported a quarterly EPS of ($0.12), missing the consensus estimate of ($0.04) by $0.08. The company had a negative net margin of 15.27% and a negative return on equity of 14.72%. The stock traded down $0.06 to $1.87. Analysts have adjusted their ratings and price targets, with some downgrading the stock. Institutional investors have modified their holdings, with 17.68% of the stock owned by them.

    Market Beat·
    US
    BIOX
    -0.63%
    Market Beat·
    US
    BIOX
    -0.63%

    Bioceres Crop ( BIOX ) Reports Q1 Loss, Lags Revenue Estimates

    Bioceres Crop (BIOX) delivered earnings and revenue surprises of -200.00% and -18.37%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Commentary·
    US
    BIOX
    -0.63%
    Zacks Commentary·
    US
    BIOX
    -0.63%

    Bioceres Crop Solutions' Q1 revenue misses estimates

    Bioceres Crop Solutions reported a 17% decline in fiscal Q1 revenue, missing analyst estimates of $90.23 million, with actual revenue at $77.50 million. However, adjusted EBITDA rose 61% to $13.60 million, surpassing expectations. The company is focusing on margin expansion, with gross margin increasing from 40% to 47%, and improving working capital efficiency. Analysts currently rate the stock as a "hold," with a median 12-month price target of $5.00, significantly above its recent closing price of $1.93.

    Reuters·
    US
    BIOX
    -0.63%
    Reuters·
    US
    BIOX
    -0.63%
    © 2025 Longbridge｜Disclaimer